Serum fentanyl concentration during conversion from intravenous to transdermal fentanyl

Serum fentanyl concentration during conversion from intravenous to transdermal fentanyl - Serum fentanyl concentration during conversion from intravenous to transdermal fentanyl

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003395

Enrollment

Registered

2010-03-29

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

the continuous intravenous infusion dose rate is decreased by 50% 6 hours after applying fentanyl patch and then stopped after another 6 hours. the continuous intravenous infusion dose rate is decreas

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligibility criteria were patients with cancer being pre-treated with continuous intravenous fentanyl, age > 20 years.

Exclusion criteria

Exclusion criteria: Patients with anemia (Hb < 8.0g/dl), hepatic dysfunction (AST and ALT levels within two times the normal upper limit, bilirubin > 2.0 mg/dl) or renal dysfunction (creatinine level > 2.0 mg/dl) were excluded.

Design outcomes

Primary

Measure	Time frame
To determine the serum fentanyl concentration during the conversion from intravenous to transdermal fentanyl	—

Countries

Japan

Contacts

Public ContactMotoo Nomura

Kansai Medical University Department of Radology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026